BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24358271)

  • 21. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
    Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
    Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
    Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM
    Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
    Kootstra NA; Matsumura R; Verma IM
    Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy for hemophilia A.
    Connelly S; Kaleko M
    Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
    Ide LM; Iwakoshi NN; Gangadharan B; Jobe S; Moot R; McCarty D; Doering CB; Spencer HT
    J Gene Med; 2010 Apr; 12(4):333-44. PubMed ID: 20209485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
    García-Martín C; Chuah MK; Van Damme A; Robinson KE; Vanzieleghem B; Saint-Remy JM; Gallardo D; Ofosu FA; Vandendriessche T; Hortelano G
    J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.
    Lin Y; Chang L; Solovey A; Healey JF; Lollar P; Hebbel RP
    Blood; 2002 Jan; 99(2):457-62. PubMed ID: 11781225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice.
    Kumaran V; Benten D; Follenzi A; Joseph B; Sarkar R; Gupta S
    J Thromb Haemost; 2005 Sep; 3(9):2022-31. PubMed ID: 16102109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
    Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
    Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high efficient FVIII variant corrects bleeding in hemophilia A mouse model.
    Mashausi DS; Roy D; Mangukiya HB; Merugu SB; Raza G; Yunus FU; Liu GS; Negi H; Li D
    Biochem Biophys Res Commun; 2022 Dec; 637():358-364. PubMed ID: 35595575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasound-mediated gene delivery specifically targets liver sinusoidal endothelial cells for sustained FVIII expression in hemophilia A mice.
    Lawton SM; Manson MA; Fan MN; Chao TY; Chen CY; Kim P; Campbell C; Cai X; Vander Kooi A; Miao CH
    Mol Ther; 2024 Apr; 32(4):969-981. PubMed ID: 38341614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A.
    Yamaki Y; Fukushima T; Yoshida N; Nishimura K; Fukuda A; Hisatake K; Aso M; Sakasai T; Kijima-Tanaka J; Miwa Y; Nakanishi M; Sumazaki R; Takada H
    Int J Hematol; 2021 Apr; 113(4):493-499. PubMed ID: 33385293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
    Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
    Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.